SAFETY OF THE SINGLE-DOSE Ad26 SARS-CoV.2 vaccine (JNJ vaccine)
24th December 2021
Pretoria: The National Department of Health has noted the Center for Disease Control (CDC), USA expressing a preference of the mRNA vaccine over Johnson and Johnson’s COVID-19 vaccine.
This is in the context of the USA having an abundance of vaccines, with over 100 million doses in the field for immediate use. The Advisory Committee on Immunization Practices (ACIP) noted during their review that any vaccine is better than being unvaccinated, and those who are unable or unwilling to receive an mRNA vaccine would continue to have access to the J&J COVID-19 vaccine.
The decision made in the context of rare adverse events and an abundance of mRNA vaccines in the USA should not undermine the roll-out of the J&J vaccine in other parts of the world. The South African Medical Research Council (SAMRC) analyzed safety data from the Sisonke Study (an open-label phase 3b implementation study that delivered almost 500 000 doses of J&J vaccine to health care workers) by monitoring adverse events (AEs) at vaccination sites, through self-reporting triggered by text messages after vaccination, health care provider reports and by active case finding.
The frequency and incidence rate of non-serious and serious AEs were evaluated from day of first vaccination (17 February 2021) until 28 days after the final vaccination (15 June 2021). Of 477,234 participants, only 10,279 (2.2%) reported AEs. Serious sideeffects were rare and occurred in only 129 health care workers. The commonest side effects were headache and body aches, followed by injection site pain and fever, and most occurred within 48 hours of vaccination.